XML 32 R21.htm IDEA: XBRL DOCUMENT

RELATED PARTIES	6 Months Ended
RELATED PARTIES	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTIES The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During the three months ended June 30, 2020 and 2019, the Company recognized net revenues of $6 million and $9 million, respectively, associated with diagnostic information services provided to its equity method investees. During the six months ended June 30, 2020 and 2019, the Company recognized net revenues of $15 million and $18 million, respectively, associated with diagnostic information services provided to its equity method investees. As of June 30, 2020 and December 31, 2019, there was $5 million and $4 million, respectively, of accounts receivable from equity method investees related to such services. During the three months ended June 30, 2020, net revenues recognized by the Company associated with diagnostic information services provided to a noncontrolling interest partner in a joint venture were not material. For the three months ended June 30, 2019, the Company recognized net revenues of $2 million associated with diagnostic information services provided to a noncontrolling interest partner in a joint venture. During the six months ended June 30, 2020 and 2019, the Company recognized net revenues of $1 million and $5 million, respectively, associated with diagnostic information services provided to a noncontrolling interest partner in a joint venture. As of December 31, 2019, there was $4 million of receivables from the noncontrolling interest partner included in accounts receivable and other assets related to such services. During both the three months ended June 30, 2020 and 2019, the Company recognized income of $4 million associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. During both the six months ended June 30, 2020 and 2019, the Company recognized income of $8 million associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. As of June 30, 2020 and December 31, 2019, there was $2 million and $1 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of both June 30, 2020 and December 31, 2019 included $2 million due to equity method investees. During the six months ended June 30, 2020 and 2019, the Company received dividends from its equity method investees of $13 million and $17 million, respectively.